Blueprint Medicines

After Roche breakup, Blueprint Medicines finds Gavreto a new home at Rigel
Fierce Pharma
Thu, 02/22/24 - 11:40 am
Rigel Pharmaceuticals
Gavreto
RET inhibitors
Blueprint Medicines
Roche
Blueprint boosts Ayvakit peak sales estimate to $2B as key rare disease expansion accelerates
Fierce Pharma
Thu, 02/15/24 - 11:13 am
Blueprint Medicines
Ayvakit
earnings
FDA Grants Regular Approval of Gavreto for Metastatic NSCLC Subset
Cure Today
Wed, 08/9/23 - 10:42 pm
Genentech
Blueprint Medicines
Gavreto
non-small cell lung cancer
Roche pulls a Gavreto approval before Blueprint severance, citing unfeasible trial
Fierce Pharma
Wed, 07/5/23 - 07:12 pm
Roche
Blueprint Medicines
cancer
Gavreto
accelerated approvals
FDA
What Will AbbVie Buy Next?
Motley Fool
Wed, 06/28/23 - 10:01 am
AbbVie
M&A
Blueprint Medicines
Krystal Biotech
Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis
Fierce Pharma
Mon, 05/22/23 - 10:07 pm
Blueprint Medicines
Ayvakit
FDA
indolent systemic mastocytosis
systemic mastocytosis
FDA lifts partial hold on Blueprint's CDK2 inhibitor
Endpoints
Wed, 03/29/23 - 09:43 am
Blueprint Medicines
cancer
CDK2 inhibitor
FDA
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
Endpoints
Mon, 02/27/23 - 10:03 am
Blueprint Medicines
FDA
Ayvakit
systemic mastocytosis
Roche and Blueprint agree to end collaboration for cancer drug Gavreto
Endpoints
Thu, 02/23/23 - 04:30 pm
Roche
Gavreto
Blueprint Medicines
cancer
Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line
Fierce Pharma
Fri, 02/17/23 - 11:21 am
Blueprint Medicines
Ayvakit
FDA
systemic mastocytosis
Blueprint drug succeeds in rare disease study important to its market prospects
BioPharma Dive
Wed, 08/17/22 - 10:55 am
Blueprint Medicines
systemic mastocytosis
clinical trials
Ayvakit
Blueprint secures access to more than $1B in funding through two new deals
BioPharma Dive
Thu, 06/30/22 - 10:21 pm
Blueprint Medicines
funding
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Riding success of Roche-partnered lung cancer drug, Blueprint makes $250M play for Lengo's preclinical work
Fierce Biotech
Mon, 11/29/21 - 11:07 am
Blueprint Medicines
M&A
Lengo Therapeutics
Scientific co-founder of Blueprint Medicines launches Recludix with $60M, 15-year Seagen exec steering the ship
Fierce Biotech
Mon, 11/15/21 - 10:40 am
Recludix Pharma
STAT inhibitors
Blueprint Medicines
funding
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Motley Fool
Thu, 08/5/21 - 10:57 am
Pfizer
M&A
Blueprint Medicines
Aurinia Pharmaceuticals
Atea Pharmaceuticals
Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines
BioSpace
Thu, 06/17/21 - 10:55 am
Blueprint Medicines
Ayvakit
MCL
systemic mastocytosis
FDA
FDA Action Alert: Blueprint, Orphazyme and Eton
BioSpace
Mon, 06/14/21 - 10:52 am
FDA
Blueprint Medicines
avapritinib
Orphazyme
arimoclomol
Eton Pharmaceuticals
Fortunes diverge for solo drug launchers
EP Vantage
Tue, 05/11/21 - 11:01 am
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
Yahoo/Benzinga
Mon, 02/15/21 - 10:37 am
earnings
FDA
G1 Therapeutics
trilaciclib
Zoetis
EXACT Sciences
Blueprint Medicines
Ironwood Pharmaceuticals

Pages